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Background
Previous studies with HIV-1 Pr55Gag virus-like particles
(VLP) produced via the baculovirus expression system
showed that these VLP are able to induce strong humoral
and cellular immune responses in mice as well as non
human primates. Based on these VLP we generated mam-
malian derived VLPs and compared them regarding their
ability to maturate and activate human monocyte derived
dendritic cells (MDDC). Furthermore, we investigated the
capacity of CD40 pseudotyped mammalian VLPs to
induce the proliferation of B cells.
Methods
Pr55Gag VLP were produced (i) either in insect cells using
the baculovirus (BV) expression system or (ii) in mamma-
lian 293T cells after transient DNA transfection. MDDC
were generated and treated with the different VLPs and
were further analysed regarding maturation and activa-
tion via surface staining of CD80, CD83, CD86, HLA-DR
as well as cytokine production (IFN, TNF, IL-6, IL-10, IL-
12). Mammalian VLP were further pseudotyped with
CD40 Ligand and examined regarding their B-cell prolif-
eration capacity.
Results
Ex vivo studies on MDDCs clearly demonstrated that VLP
of BV origin, but not VLP produced in mammalian cells
triggered MDDC maturation, activation and cytokine
secretion. Furthermore CD40 ligand pseudotyped mam-
malian cell derived VLP are able to induce B-cell prolifer-
ation whereas the other VLP preparations showed no
effect.
Conclusion
These results clearly indicate that the potency of VLP to
induce innate immune responses is not an intrinsic prop-
erty of VLP. In addition pseudotyped VLPs, are the next
forefront in vaccine development to stimulate and induce
the innate immunity.
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